X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs MYLAN (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   MYLAN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
MYLAN
Dec-14
GLENMARK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9933,830-   
Low Rs7292,699-   
Sales per share (Unadj.) Rs325.51,311.3-  
Earnings per share (Unadj.) Rs39.3158.0-  
Cash flow per share (Unadj.) Rs48.7254.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs159.2651.9-  
Shares outstanding (eoy) m282.17378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x2.62.5 106.2%   
Avg P/E ratio x21.920.7 106.0%  
P/CF ratio (eoy) x17.712.8 137.8%  
Price / Book Value ratio x5.45.0 108.0%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m242,9911,235,346 19.7%   
No. of employees `00013.025.0 51.9%   
Total wages/salary Rs m16,4080-   
Avg. sales/employee Rs Th7,083.919,846.6 35.7%   
Avg. wages/employee Rs Th1,265.40-   
Avg. net profit/employee Rs Th855.12,390.8 35.8%   
INCOME DATA
Net Sales Rs m91,857496,164 18.5%  
Other income Rs m374-2,892 -12.9%   
Total revenues Rs m92,230493,272 18.7%   
Gross profit Rs m20,367123,398 16.5%  
Depreciation Rs m2,64436,441 7.3%   
Interest Rs m2,37321,402 11.1%   
Profit before tax Rs m15,72462,663 25.1%   
Minority Interest Rs m0-257 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8272,635 145.2%   
Profit after tax Rs m11,08859,771 18.5%  
Gross profit margin %22.224.9 89.2%  
Effective tax rate %24.34.2 578.8%   
Net profit margin %12.112.0 100.2%  
BALANCE SHEET DATA
Current assets Rs m68,746436,194 15.8%   
Current liabilities Rs m27,027341,017 7.9%   
Net working cap to sales %45.419.2 236.8%  
Current ratio x2.51.3 198.9%  
Inventory Days Days8578 108.9%  
Debtors Days Days96107 89.1%  
Net fixed assets Rs m24,132114,786 21.0%   
Share capital Rs m28217,546 1.6%   
"Free" reserves Rs m44,6430-   
Net worth Rs m44,925246,643 18.2%   
Long term debt Rs m45,363368,460 12.3%   
Total assets Rs m117,639993,454 11.8%  
Interest coverage x7.63.9 194.1%   
Debt to equity ratio x1.01.5 67.6%  
Sales to assets ratio x0.80.5 156.3%   
Return on assets %11.48.2 140.0%  
Return on equity %24.724.2 101.8%  
Return on capital %19.113.6 140.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m48,0680-   
CASH FLOW
From Operations Rs m6,57465,221 10.1%  
From Investments Rs m-7,124-51,435 13.8%  
From Financial Activity Rs m5,432-17,186 -31.6%  
Net Cashflow Rs m1,992-3,400 -58.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: IPCA LABS  DISHMAN PHARMA  ALKEM LABORATORIES  FULFORD INDIA  NATCO PHARMA  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views On News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS